- Genprex Inc Global One Media Interview TranscriptJun 22, 2023
- Genprex Inc at Sidoti & Company May Micro-Cap Virtual Conference TranscriptMay 11, 2023
- Genprex Inc KOL Event: Novel Gene Therapy to Treat Type 1 Diabetes TranscriptApr 12, 2023
- Genprex Inc at LD Micro Main Event TranscriptOct 26, 2022
- Genprex Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 12, 2022
- Genprex Inc at LD Micro Invitational Conference (Virtual) TranscriptJun 08, 2022
- Genprex Inc at Noble Capital Markets Investor Conference (Virtual) TranscriptApr 20, 2022
- Genprex Inc at Benzinga Healthcare Small Cap Conference (Virtual) TranscriptSep 29, 2021
- Genprex Inc C-Suite Interview with Noble Capital Markets TranscriptApr 22, 2021
- Cell and Gene Meeting on Mesa - Genprex TranscriptJan 08, 2021
- Genprex launches new branding for its lead drug REQORSA in preparation for upcoming studies TranscriptNov 06, 2020
- Genprex (GNPX) Virtual Road Show with CEO Rodney Varner TranscriptSep 15, 2020
- Genprex (GNPX) Channelchek C-Suite Series, CEO Rodney Varner interview with Noble's Dr. Ahu Demir TranscriptAug 04, 2020
Genprex Inc at LD Micro Invitational Conference (Virtual) Transcript
Financial Officer for Genprex. We are a gene-therapy company. A lot of people here, gene therapies, their initial reaction is niche or rare diseases. And we are focused on treating very large patient populations specifically in cancer and diabetes.
So our forward-looking statements. I highly encourage you, anybody that's interested in evaluating our company or a potential investment, to review these statements as well as looking at our recently filed 10-K for our risk factors. All of which can be found on our company website.
Here's a financial snapshot of the company. Market cap is around $73 million. Like other biotechs, we believe that we're undervalued at this point given the market conditions. But the big thing I would highlight on this chart specifically is our cash position.
We sit at $34.5 million as of the end of the first quarter of this year. A pretty healthy balance, and we have provided guidance that we believe that that amount of cash will be sufficient for operations to last us into the beginning of 2024. Additionally, we have no
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)